Predictors of target lesion failure after treatment of left main, bifurcation, or chronic total occlusion lesions with ultrathin-strut drug-eluting coronary stents in the ULTRA registry.
Humans
Male
Middle Aged
Aged
Sirolimus
Retrospective Studies
Stroke Volume
Treatment Outcome
Percutaneous Coronary Intervention
/ adverse effects
Ventricular Function, Left
Myocardial Infarction
/ etiology
Prosthesis Design
Stents
/ adverse effects
Registries
Coronary Artery Disease
/ diagnostic imaging
chronic total occlusion
coronary bifurcation
drug-eluting stents
left main disease
percutaneous coronary intervention (PCI)
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
18
04
2023
received:
19
01
2023
accepted:
13
05
2023
medline:
7
8
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
Data about the long-term performance of new-generation ultrathin-strut drug-eluting stents (DES) in challenging coronary lesions, such as left main (LM), bifurcation, and chronic total occlusion (CTO) lesions are scant. The international multicenter retrospective observational ULTRA study included consecutive patients treated from September 2016 to August 2021 with ultrathin-strut (<70 µm) DES in challenging de novo lesions. Primary endpoint was target lesion failure (TLF): composite of cardiac death, target-lesion revascularization (TLR), target-vessel myocardial infarction (TVMI), or definite stent thrombosis (ST). Secondary endpoints included all-cause death, acute myocardial infarction (AMI), target vessel revascularization, and TLF components. TLF predictors were assessed with Cox multivariable analysis. Of 1801 patients (age: 66.6 ± 11.2 years; male: 1410 [78.3%]), 170 (9.4%) experienced TLF during follow-up of 3.1 ± 1.4 years. In patients with LM, CTO, and bifurcation lesions, TLF rates were 13.5%, 9.9%, and 8.9%, respectively. Overall, 160 (8.9%) patients died (74 [4.1%] from cardiac causes). AMI and TVMI rates were 6.0% and 3.2%, respectively. ST occurred in 11 (1.1%) patients while 77 (4.3%) underwent TLR. Multivariable analysis identified the following predictors of TLF: age, STEMI with cardiogenic shock, impaired left ventricular ejection fraction, diabetes, and renal dysfunction. Among the procedural variables, total stent length increased TLF risk (HR: 1.01, 95% CI: 1-1.02 per mm increase), while intracoronary imaging reduced the risk substantially (HR: 0.35, 95% CI: 0.12-0.82). Ultrathin-strut DES showed high efficacy and satisfactory safety, even in patients with challenging coronary lesions. Yet, despite using contemporary gold-standard DES, the association persisted between established patient- and procedure-related features of risk and impaired 3-year clinical outcome.
Sections du résumé
BACKGROUND
Data about the long-term performance of new-generation ultrathin-strut drug-eluting stents (DES) in challenging coronary lesions, such as left main (LM), bifurcation, and chronic total occlusion (CTO) lesions are scant.
METHODS
The international multicenter retrospective observational ULTRA study included consecutive patients treated from September 2016 to August 2021 with ultrathin-strut (<70 µm) DES in challenging de novo lesions. Primary endpoint was target lesion failure (TLF): composite of cardiac death, target-lesion revascularization (TLR), target-vessel myocardial infarction (TVMI), or definite stent thrombosis (ST). Secondary endpoints included all-cause death, acute myocardial infarction (AMI), target vessel revascularization, and TLF components. TLF predictors were assessed with Cox multivariable analysis.
RESULTS
Of 1801 patients (age: 66.6 ± 11.2 years; male: 1410 [78.3%]), 170 (9.4%) experienced TLF during follow-up of 3.1 ± 1.4 years. In patients with LM, CTO, and bifurcation lesions, TLF rates were 13.5%, 9.9%, and 8.9%, respectively. Overall, 160 (8.9%) patients died (74 [4.1%] from cardiac causes). AMI and TVMI rates were 6.0% and 3.2%, respectively. ST occurred in 11 (1.1%) patients while 77 (4.3%) underwent TLR. Multivariable analysis identified the following predictors of TLF: age, STEMI with cardiogenic shock, impaired left ventricular ejection fraction, diabetes, and renal dysfunction. Among the procedural variables, total stent length increased TLF risk (HR: 1.01, 95% CI: 1-1.02 per mm increase), while intracoronary imaging reduced the risk substantially (HR: 0.35, 95% CI: 0.12-0.82).
CONCLUSIONS
Ultrathin-strut DES showed high efficacy and satisfactory safety, even in patients with challenging coronary lesions. Yet, despite using contemporary gold-standard DES, the association persisted between established patient- and procedure-related features of risk and impaired 3-year clinical outcome.
Substances chimiques
Sirolimus
W36ZG6FT64
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
221-232Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873-2891.
Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISARSTEREO) trial. Circulation. 2001;103:2816-2821.
D'Ascenzo F, De Filippo O, Elia E, et al. Percutaneous vs. surgical revascularization for patients with unprotected left main stenosis: a meta-analysis of 5-year follow-up randomized controlled trials. Eur Heart J-Qual Care Clin Outcomes. 2021;7(5):476-485.
Iannaccone M, D'Ascenzo F, Frangieh AH, et al. Impact of an optical coherence tomography guided approach in acute coronary syndromes: a propensity matched analysis from the international FORMIDABLE-CARDIOGROUP IV and USZ registry. Catheter Cardiovasc Interv. 2017;90(2):E46-E52.
D'Ascenzo F, Omedè P, De Filippo O, et al. Impact of final kissing balloon and of imaging on patients treated on unprotected left main coronary artery with thin-strut stents (from the RAIN-CARDIOGROUP VII study). Am J Cardiol. 2019;123(10):1610-1619.
Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-term safety of drug-eluting and bare-metal stents. JACC. 2015;65(23):2496-2507.
Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-1409.
Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. Circulation. 2018;138(20):2216-2226.
Kandzari DE, Koolen JJ, Doros G, et al. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization. JACC: Cardiovasc Interv. 2020;13(11):1343-1353.
von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388(10060):2607-2617.
Zaman A, de Winter RJ, Kogame N, et al. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019;393(10175):987-997.
Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390:1843-52.
Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165.
Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.
Medina A, de Lezo JS, Pan M. Una clasificación simple de las lesiones coronarias en bifurcación. Rev Esp Cardiol. 2006;59(2):183.
Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. JACC. 2016;68(17):1851-1864.
Chen SL, Sheiban I, Xu B, et al. Impact of the complexity of bifurcation lesions treated with drug-eluting stents. JACC: Cardiovasc Interv. 2014;7(11):1266-1276.
Garcia-Garcia HM, McFadden EP, Farb A, et al. Standardized end point definitions for coronary intervention trials. Eur Heart J. 2018;39(23):2192-2207.
Buiten RA, Ploumen EH, Zocca P, et al. Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents. JACC: Cardiovasc Interv. 2019;12(17):1650-1660.
de Winter RJ, Zaman A, Hara H, et al. Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial. EuroIntervention. 2022;18:492-502.
Zivelonghi C, Teeuwen K, Agostoni P, et al. Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: insights from the randomized PRISON IV trial. J Interv Cardiol. 2018;31:580-587.
Zivelonghi C, Agostoni P, Teeuwen K, et al. 3-year clinical outcomes of the PRISON-IV trial. JACC: Cardiovasc Interv. 2019;12(17):1747-1749.
Gaido L, D'Ascenzo F, Imori Y, et al. Impact of kissing balloon in patients treated with ultrathin stents for left main lesions and bifurcations: an analysis from the RAIN-CARDIOGROUP VII study. Circulation: Cardiovasc Interv. 2020;13(3):e008325.
Yager N, Schulman-Marcus J, Torosoff M. Coronary anatomy and comorbidities impact on elective PCI outcomes in left main and multivessel coronary artery disease. Catheter Cardiovasc Interv. 2021;98(3):436-444.
Collet C, Capodanno D, Onuma Y, et al. Left main coronary artery disease: pathophysiology, diagnosis, and treatment. Nat Rev Cardiol. 2018;15(6):321-331.
Gallone G, Kang J, Bruno F, et al. Impact of left ventricular ejection fraction on procedural and long-term outcomes of bifurcation percutaneous coronary intervention. Am J Cardiol. 2022;172:18-25.
Pedersen F, Butrymovich V, Kelbaek H, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. JACC. 2014;64(20):2101-2108.
De Filippo O, D'Ascenzo F, Raposeiras-Roubin S, et al. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. Eur Heart J-Cardiovasc Pharmacotherapy. 2020;6(1):31-42.
Koskinas KC, Siontis GCM, Piccolo R, et al. Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients. Circulation: Cardiovasc Interv. 2016; 9(2):e003255.
Iglesias JF, Degrauwe S, Cimci M, et al. Differential effects of newer-generation ultrathin-strut versus thicker-strut drug-eluting stents in chronic and acute coronary syndromes. JACC: Cardiovasc Interv. 2021;14(22):2461-2473.
Gallone G, D'Ascenzo F, Conrotto F, et al. Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. Catheter Cardiovasc Interv. 2021;97(2):E227-E236.
Zhang JJ, Ye F, Xu K, et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. Eur Heart J. 2020;41(27):2523-2536.
Maehara A, Mintz GS, Witzenbichler B, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents. Circulation: Cardiovasc Interv. 2018;11(11):e006243.
Hong SJ, Mintz GS, Ahn CM, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation: 5-year follow-up of the IVUS-XPL randomized trial. JACC. Cardiovasc Interv. 2020;13(1):62-71.
Elgendy IY, Ha LD, Elbadawi A, et al. Temporal trends in inpatient use of intravascular imaging among patients undergoing percutaneous coronary intervention in the United States. JACC: Cardiovasc Interv. 2018;11:913-915.